Bessemer Group’s Nuvation Bio NUVB Stock Holding History

Bessemer Group’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-122	Closed	–	–	2651
2025 Q2	$0	Hold	122	–	–	﹤0.01%	2572
2025 Q1	$0	Buy	+122	New	+$278	﹤0.01%	2653

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bessemer Group's NUVB Position: Q3 2025 in Review

Bessemer Group sold out of Nuvation Bio (NUVB) in Q3 2025, closing a stake of 122 shares.

Bessemer Group first reported a position in NUVB in Q1 2025 and held it in 2 quarters. The position peaked at $0 in Q2 2025. 203 funds tracked by Wall St. Rank hold NUVB as of Q3 2025.

Bessemer Group reported no remaining Nuvation Bio position as of Q3 2025 after selling out during the quarter.
Bessemer Group sold 122 Nuvation Bio shares in Q3 2025.
Bessemer Group first reported a position in Nuvation Bio in Q1 2025 and held it in 2 quarters.
Bessemer Group's Nuvation Bio position peaked at $0 in Q2 2025.
203 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.